Drugs / SIBP MMR Vaccine
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT06399003 | Jun → Sep 2024 | primary viral infectious disease | Shanghai Institute Of Biological Products | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SIBP MMR Vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06399003 ↗ |
| Known as | Shanghai MMR | “This is a live attenuated measles, mumps, and rubella combined vaccine (Shanghai MMR) in a freeze-dried powder form, developed and manufactured by Shanghai Institute of...” NCT06399003 ↗ |
| Modality | Vaccine | “This is a live attenuated measles, mumps, and rubella combined vaccine” NCT06399003 ↗ |